LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 10 of total 146

Search options

  1. Article: Fluoroquinolones: mechanisms of action and resistance.

    Bryskier, A

    International journal of antimicrobial agents

    2008  Volume 2, Issue 3, Page(s) 151–183

    Abstract: The mechanism of action and the mechanism of resistance of the 4-quinolones are complex and poorly understood. The first barrier these molecules must cross is the bacterial outer membrane. In gram-negative species, 4-quinolones pass through either the ... ...

    Abstract The mechanism of action and the mechanism of resistance of the 4-quinolones are complex and poorly understood. The first barrier these molecules must cross is the bacterial outer membrane. In gram-negative species, 4-quinolones pass through either the porins or lipopolysaccharides (or both) depending on their chemical nature. The cellular target is the DNA of the bacterial chromosome. 4-Quinolones mainly modify the activity of topoisomerase II or DNA gyrase, but also that of topoisomerase I and IV. Any damage to the bacterial genome will induce a stress response which consists in the SOS response, chaperonin synthesis or the generation of oxygen free radicals. Peptidoglycan synthesis is also modified, as shown by the inhibition of PBP(3) activity. Mechanism of resistance involves mutations on gyrA and gyrB genes. gyrA Mutations on the chromosome are responsible for a high level of resistance due to a modification of the A subunit of DNA gyrase, mutations on gyrB gene are responsible for a low level of resistance; the combination of both mutations leads to a high level of resistance. Other mutations are responsible for increasing the MIC, such as a norA mutation in S. aureus. The antibacterial activity of the various molecules is different and, as a result, there is not a single mechanism of action or resistance, but rather a common trunk on which additional mechanisms are grafted.
    Language English
    Publishing date 2008-05-23
    Publishing country Netherlands
    Document type Journal Article
    ZDB-ID 1093977-5
    ISSN 1872-7913 ; 0924-8579
    ISSN (online) 1872-7913
    ISSN 0924-8579
    DOI 10.1016/0924-8579(93)90052-7
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 3368: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (2.OG)
    ab Jg. 2022: Lesesaal (EG)
    Zs.MO 500: Show issues

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  2. Article ; Online: Dual beta-lactam-fluoroquinolone compounds: a novel approach to antibacterial treatment.

    Bryskier, A

    Expert opinion on investigational drugs

    2005  Volume 6, Issue 10, Page(s) 1479–1499

    Abstract: Codrugs comprise a beta-lactam-fluoroquinolone antibacterial hybrid. These new agents have been developed with the aim of enhancing the antibacterial spectrum of current therapies, overcoming intrinsic and acquired resistance, and diminishing severe side- ...

    Abstract Codrugs comprise a beta-lactam-fluoroquinolone antibacterial hybrid. These new agents have been developed with the aim of enhancing the antibacterial spectrum of current therapies, overcoming intrinsic and acquired resistance, and diminishing severe side-effects. A few compounds, including Ro 23-9424, have entered Phase I clinical trials. Furthermore, a series of oral codrugs have been synthesised, although clear oral bioavailability has not yet been demonstrated. New drugs are urgently needed to treat Gram-positive resistant bacteria.
    Language English
    Publishing date 2005-06-07
    Publishing country England
    Document type Journal Article
    ZDB-ID 1182884-5
    ISSN 1744-7658 ; 0967-8298 ; 1354-3784
    ISSN (online) 1744-7658
    ISSN 0967-8298 ; 1354-3784
    DOI 10.1517/13543784.6.10.1479
    Database MEDical Literature Analysis and Retrieval System OnLINE

    Full text online

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 3739: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (2.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  3. Article ; Online: New research in macrolides and ketolides since 1997.

    Bryskier, A

    Expert opinion on investigational drugs

    2005  Volume 8, Issue 8, Page(s) 1171–1194

    Abstract: Macrolide and ketolide antibacterials remain a very dynamically active group. To overcome erythromycin A resistance within Gram-positive cocci and bacteria, novel compounds have been semi-synthesised, such as ketolides and C-4'' carbamate ... ...

    Abstract Macrolide and ketolide antibacterials remain a very dynamically active group. To overcome erythromycin A resistance within Gram-positive cocci and bacteria, novel compounds have been semi-synthesised, such as ketolides and C-4'' carbamate erythromycylamine derivatives. The continual efforts of those studying macrolides have led to molecular level investigations into the mechanism of action of these antibacterials. Among all novel derivatives, only telithromycin and AB-773 are currently under development. No real novel developments have been seen with the 15- and 16-membered ring macrolides, however, research is also continuing in this area. This review is an update of our knowledge in the field of macrolides.
    Language English
    Publishing date 2005-06-07
    Publishing country England
    Document type Journal Article
    ZDB-ID 1182884-5
    ISSN 1744-7658 ; 0967-8298 ; 1354-3784
    ISSN (online) 1744-7658
    ISSN 0967-8298 ; 1354-3784
    DOI 10.1517/13543784.8.8.1171
    Database MEDical Literature Analysis and Retrieval System OnLINE

    Full text online

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 3739: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (2.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  4. Article ; Online: Novelties in the field of macrolides.

    Bryskier, A

    Expert opinion on investigational drugs

    2005  Volume 6, Issue 11, Page(s) 1697–1709

    Abstract: Research in the field of macrolide antibiotics has continued. The aims of research efforts are quite different with 14-, 15- and 16-membered ring macrolides. A review of 14- and 15-membered ring macrolides covering the period up to 1995 was published in ... ...

    Abstract Research in the field of macrolide antibiotics has continued. The aims of research efforts are quite different with 14-, 15- and 16-membered ring macrolides. A review of 14- and 15-membered ring macrolides covering the period up to 1995 was published in a previous issue of this journal.
    Language English
    Publishing date 2005-06-07
    Publishing country England
    Document type Journal Article
    ZDB-ID 1182884-5
    ISSN 1744-7658 ; 0967-8298 ; 1354-3784
    ISSN (online) 1744-7658
    ISSN 0967-8298 ; 1354-3784
    DOI 10.1517/13543784.6.11.1697
    Database MEDical Literature Analysis and Retrieval System OnLINE

    Full text online

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 3739: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (2.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  5. Article ; Online: Novelties in the field of fluoroquinolones.

    Bryskier, A

    Expert opinion on investigational drugs

    2005  Volume 6, Issue 9, Page(s) 1227–1245

    Abstract: The field of fluoroquinolone research is rapidly expanding. Bacterial targets are constantly changing to meet the demands of resistance. At present, new compounds are targeting respiratory pathogens, such as Streptococcus pneumoniae. However, problems ... ...

    Abstract The field of fluoroquinolone research is rapidly expanding. Bacterial targets are constantly changing to meet the demands of resistance. At present, new compounds are targeting respiratory pathogens, such as Streptococcus pneumoniae. However, problems such as phototoxicity, cardiotoxicity and CNS disturbances must be overcome. New promising fluoroquinolones include: HSR 903, LB 20304 and BAY 12-8039. Research in the field of mycobacteria, especially for Mycobacterium tuberculosis, is also underway.
    Language English
    Publishing date 2005-06-07
    Publishing country England
    Document type Journal Article
    ZDB-ID 1182884-5
    ISSN 1744-7658 ; 0967-8298 ; 1354-3784
    ISSN (online) 1744-7658
    ISSN 0967-8298 ; 1354-3784
    DOI 10.1517/13543784.6.9.1227
    Database MEDical Literature Analysis and Retrieval System OnLINE

    Full text online

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 3739: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (2.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  6. Article ; Online: Novelties in the field of parenteral cephem antibacterials since 1993.

    Bryskier, A

    Expert opinion on investigational drugs

    2005  Volume 6, Issue 3, Page(s) 305–320

    Abstract: There is still considerable interest in cephem antibacterial agents. In fact, there are a significant number of patents submitted for this antibacterial class. All the new cephem derivatives, independent of which group they belong to (III to V), possess ... ...

    Abstract There is still considerable interest in cephem antibacterial agents. In fact, there are a significant number of patents submitted for this antibacterial class. All the new cephem derivatives, independent of which group they belong to (III to V), possess a 2-amino-5-thiazolyl or a 5-amino-2-thiadiazolyl ring with an oxime group (at position 7 of the cephem nucleus). At position 3, they have a C-3' quaternary ammonium moiety. Research has focused on the following structural modifications: the nature of the oxime residues and the charged azolium heterocycle, and the addition of the vinylogous chain. The aim of researchers is to increase the overall activity of these compounds against Gram-negative bacilli, including against isolates producing type 1 beta-lactamases or extended spectrum beta-lactamases (Enterobacteriaceae). Non-fermentative Gram-negative bacilli are now included in the first screening process, in addition to Pseudomonas aeruginosa. Extensive research is ongoing with the aim of solving the MRSA problem. New promising entities have been reported.
    Language English
    Publishing date 2005-06-07
    Publishing country England
    Document type Journal Article
    ZDB-ID 1182884-5
    ISSN 1744-7658 ; 0967-8298 ; 1354-3784
    ISSN (online) 1744-7658
    ISSN 0967-8298 ; 1354-3784
    DOI 10.1517/13543784.6.3.305
    Database MEDical Literature Analysis and Retrieval System OnLINE

    Full text online

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 3739: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (2.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  7. Article ; Online: Anti-MRSA agents: under investigation, in the exploratory phase and clinically available.

    Bryskier, André

    Expert review of anti-infective therapy

    2005  Volume 3, Issue 4, Page(s) 505–553

    Abstract: Staphylococcal infections are difficult to treat due to the rapid emergence of methicillin-resistant staphylococci and, unfortunately, vancomycin-intermediate or -resistant staphylococci. Numerous alternative treatments are urgently required. In this ... ...

    Abstract Staphylococcal infections are difficult to treat due to the rapid emergence of methicillin-resistant staphylococci and, unfortunately, vancomycin-intermediate or -resistant staphylococci. Numerous alternative treatments are urgently required. In this special report, intensive research of new molecules is highlighted--in known antibacterial families and new medicinal chemical entities.
    MeSH term(s) Anti-Bacterial Agents/chemistry ; Anti-Bacterial Agents/pharmacology ; Anti-Bacterial Agents/therapeutic use ; Humans ; Methicillin Resistance ; Staphylococcal Infections/drug therapy ; Staphylococcal Infections/epidemiology ; Staphylococcal Infections/microbiology ; Staphylococcus aureus/drug effects
    Chemical Substances Anti-Bacterial Agents
    Language English
    Publishing date 2005-08
    Publishing country England
    Document type Journal Article ; Review
    ZDB-ID 2181279-2
    ISSN 1744-8336 ; 1478-7210
    ISSN (online) 1744-8336
    ISSN 1478-7210
    DOI 10.1586/14787210.3.4.505
    Database MEDical Literature Analysis and Retrieval System OnLINE

    Full text online

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 6106: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  8. Article: Viridans group streptococci: a reservoir of resistant bacteria in oral cavities.

    Bryskier, A

    Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases

    2002  Volume 8, Issue 2, Page(s) 65–69

    Abstract: The worldwide spread of erythromycin A-resistant streptococci, including Streptococcus pneumoniae, is of concern. Many studies have demonstrated that the viridans group streptococci can be a reservoir of erythromycin A resistance. Within oral ... ...

    Abstract The worldwide spread of erythromycin A-resistant streptococci, including Streptococcus pneumoniae, is of concern. Many studies have demonstrated that the viridans group streptococci can be a reservoir of erythromycin A resistance. Within oral streptoccoci, an important difference in the susceptibility pattern has been noted. The purpose of this short editorial is to highlight the importance of this group of bacteria as a reservoir of resistance to erythromycin A and the possible transfer of resistance to S. pneumoniae and S. pyogenes.
    MeSH term(s) Anti-Bacterial Agents/pharmacology ; Disease Reservoirs ; Drug Resistance, Bacterial ; Erythromycin/pharmacology ; Humans ; Microbial Sensitivity Tests ; Mouth/microbiology ; Streptococcal Infections/microbiology ; Streptococcus/classification ; Streptococcus/drug effects ; Streptococcus/genetics ; Streptococcus/isolation & purification
    Chemical Substances Anti-Bacterial Agents ; Erythromycin (63937KV33D)
    Language English
    Publishing date 2002-02
    Publishing country England
    Document type Editorial
    ZDB-ID 1328418-6
    ISSN 1469-0691 ; 1198-743X ; 1470-9465
    ISSN (online) 1469-0691
    ISSN 1198-743X ; 1470-9465
    DOI 10.1046/j.1198-743x.2001.00398.x
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 4541: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (2.OG)
    ab Jg. 2022: Lesesaal (EG)
    Zs.MO 284: Show issues

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  9. Article: Bacillus anthracis and antibacterial agents.

    Bryskier, A

    Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases

    2002  Volume 8, Issue 8, Page(s) 467–478

    Abstract: Anthrax is one of the oldest threats to humankind, and remains endemic in animals in many parts of the world. Human cases are infrequent, and some result from biological warfare. This review summarizes the current knowledge on the antibacterial activity ... ...

    Abstract Anthrax is one of the oldest threats to humankind, and remains endemic in animals in many parts of the world. Human cases are infrequent, and some result from biological warfare. This review summarizes the current knowledge on the antibacterial activity of available antibiotics. For potential use in the most severe cases of anthrax, antibacterials need to exhibit potent in vitro activity, intracellular bioactivity, and suitable locations in lymph nodes. In animal models, it has been shown that doxycycline and fluoroquinolones are the most active compounds. There is a lack of data for animal models for macrolides and ketolides, some of them exhibiting good in vitro activity. However, systemic anthrax (inhalation or gastrointestinal) is mainly due to anthrax toxin, and therapy directed against intoxication is needed as basic treatment.
    MeSH term(s) Animals ; Anthrax/drug therapy ; Anthrax/epidemiology ; Anthrax/microbiology ; Anthrax/prevention & control ; Anti-Bacterial Agents/administration & dosage ; Anti-Bacterial Agents/pharmacology ; Anti-Bacterial Agents/therapeutic use ; Bacillus anthracis/drug effects ; Bacillus anthracis/genetics ; Bacillus anthracis/physiology ; Biological Warfare/prevention & control ; Disease Models, Animal ; Disease Outbreaks ; Drug Resistance, Bacterial/genetics ; Humans ; Microbial Sensitivity Tests
    Chemical Substances Anti-Bacterial Agents
    Language English
    Publishing date 2002-08
    Publishing country England
    Document type Journal Article ; Review
    ZDB-ID 1328418-6
    ISSN 1469-0691 ; 1198-743X ; 1470-9465
    ISSN (online) 1469-0691
    ISSN 1198-743X ; 1470-9465
    DOI 10.1046/j.1469-0691.2002.00527.x
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 4541: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (2.OG)
    ab Jg. 2022: Lesesaal (EG)
    Zs.MO 284: Show issues

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  10. Article: Telithromycin--an innovative ketolide antimicrobials.

    Bryskier, A

    The Japanese journal of antibiotics

    2001  Volume 54 Suppl A, Page(s) 64–69

    MeSH term(s) Anti-Bacterial Agents/pharmacokinetics ; Anti-Bacterial Agents/pharmacology ; Bacterial Proteins/biosynthesis ; Drug Resistance, Microbial/genetics ; Gram-Positive Bacteria/drug effects ; Humans ; Ketolides ; Macrolides ; Mutation ; Peptidyl Transferases ; RNA, Ribosomal, 23S/genetics ; Ribosomes/metabolism
    Chemical Substances Anti-Bacterial Agents ; Bacterial Proteins ; Ketolides ; Macrolides ; RNA, Ribosomal, 23S ; Peptidyl Transferases (EC 2.3.2.12) ; telithromycin (KI8H7H19WL)
    Language English
    Publishing date 2001-02
    Publishing country Japan
    Document type Journal Article ; Review
    ZDB-ID 390804-5
    ISSN 0368-2781
    ISSN 0368-2781
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.B 811: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

To top